Curation
PascalFrancis
Racine
Curation
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur les pandémies grippales

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades

Identifieur interne : 001D40 ( PascalFrancis/Curation ); précédent : 001D39; suivant : 001D41

Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades

Auteurs : Tze-Minn Mak [Singapour] ; Brendon J. Hanson [Singapour] ; Yee-Joo Tan [Singapour]

Source :

RBID : Pascal:14-0168547

Descripteurs français

English descriptors

Abstract

The persistent evolution and circulation of highly pathogenic avian influenza H5N1 viruses pose a serious threat to global heath and hamper pandemic preparedness through conventional vaccine strategies. Combination passive immunotherapy using non-competing neutralizing antibodies has been proposed as a viable alternative to provide broad protection against drift variants. This necessitates the pre-pandemic production and characterization of potently neutralizing monoclonal antibodies (MAbs). One such antibody, MAb 9F4 was shown to provide heterologous protection against multiple H5N1 clade viruses, including one of the recently designated subclades, namely 2.3.4, through binding to a novel epitope, warranting its further development and characterization as a therapeutic candidate. In this study, the conversion of MAb 9F4 from mouse IgG2b to mouse-human chimeric (xi) IgG1 and IgA1 was achieved. These chimeric MAb versions were found to retain high degrees of binding and neutralizing activity against H5N1. The demonstration that xi-IgA1-9F4 retains a fairly high level of neutralizing activity, which is ˜10-fold lower than the corresponding xi-IgG1 isotype, suggests that this MAb could be further developed and engineered for intranasal administration.
pA  
A01 01  1    @0 0166-3542
A02 01      @0 ARSRDR
A03   1    @0 Antivir. res.
A05       @2 107
A08 01  1  ENG  @1 Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades
A11 01  1    @1 MAK (Tze-Minn)
A11 02  1    @1 HANSON (Brendon J.)
A11 03  1    @1 TAN (Yee-Joo)
A14 01      @1 NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore @3 SGP @Z 1 aut.
A14 02      @1 Defence Medical and Environmental Research Institute, DSO National Laboratories @3 SGP @Z 2 aut.
A14 03      @1 Infrastructure, Technology and Translational Division, Institute of Molecular and Cell Biology, A*STAR @3 SGP @Z 3 aut.
A14 04      @1 Department of Microbiology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore @3 SGP @Z 3 aut.
A20       @1 76-83
A21       @1 2014
A23 01      @0 ENG
A43 01      @1 INIST @2 18839 @5 354000502765430110
A44       @0 0000 @1 © 2014 INIST-CNRS. All rights reserved.
A45       @0 1 p.1/4
A47 01  1    @0 14-0168547
A60       @1 P
A61       @0 A
A64 01  1    @0 Antiviral research
A66 01      @0 GBR
C01 01    ENG  @0 The persistent evolution and circulation of highly pathogenic avian influenza H5N1 viruses pose a serious threat to global heath and hamper pandemic preparedness through conventional vaccine strategies. Combination passive immunotherapy using non-competing neutralizing antibodies has been proposed as a viable alternative to provide broad protection against drift variants. This necessitates the pre-pandemic production and characterization of potently neutralizing monoclonal antibodies (MAbs). One such antibody, MAb 9F4 was shown to provide heterologous protection against multiple H5N1 clade viruses, including one of the recently designated subclades, namely 2.3.4, through binding to a novel epitope, warranting its further development and characterization as a therapeutic candidate. In this study, the conversion of MAb 9F4 from mouse IgG2b to mouse-human chimeric (xi) IgG1 and IgA1 was achieved. These chimeric MAb versions were found to retain high degrees of binding and neutralizing activity against H5N1. The demonstration that xi-IgA1-9F4 retains a fairly high level of neutralizing activity, which is ˜10-fold lower than the corresponding xi-IgG1 isotype, suggests that this MAb could be further developed and engineered for intranasal administration.
C02 01  X    @0 002B02S05
C02 02  X    @0 002B05C02C
C03 01  X  FRE  @0 Caractérisation @5 01
C03 01  X  ENG  @0 Characterization @5 01
C03 01  X  SPA  @0 Caracterización @5 01
C03 02  X  FRE  @0 Anticorps monoclonal @5 02
C03 02  X  ENG  @0 Monoclonal antibody @5 02
C03 02  X  SPA  @0 Anticuerpo monoclonal @5 02
C03 03  X  FRE  @0 Multiple @5 03
C03 03  X  ENG  @0 Multiple @5 03
C03 03  X  SPA  @0 Múltiple @5 03
C03 04  X  FRE  @0 Grippe @5 04
C03 04  X  ENG  @0 Influenza @5 04
C03 04  X  SPA  @0 Gripe @5 04
C03 05  X  FRE  @0 Anticorps neutralisant @5 05
C03 05  X  ENG  @0 Neutralizing antibody @5 05
C03 05  X  SPA  @0 anticuerpo neutralizante @5 05
C03 06  X  FRE  @0 Neutralisation @5 06
C03 06  X  ENG  @0 Neutralization @5 06
C03 06  X  SPA  @0 Neutralización @5 06
C03 07  X  FRE  @0 Hémagglutinine @5 07
C03 07  X  ENG  @0 Hemagglutinin @5 07
C03 07  X  SPA  @0 Hemoaglutinina @5 07
C03 08  X  FRE  @0 Influenzavirus A(H5N1) @4 CD @5 96
C03 08  X  ENG  @0 Influenzavirus A(H5N1) @4 CD @5 96
C07 01  X  FRE  @0 Virose
C07 01  X  ENG  @0 Viral disease
C07 01  X  SPA  @0 Virosis
C07 02  X  FRE  @0 Infection
C07 02  X  ENG  @0 Infection
C07 02  X  SPA  @0 Infección
N21       @1 209
N44 01      @1 OTO
N82       @1 OTO

Links toward previous steps (curation, corpus...)

Links to Exploration step

Pascal:14-0168547

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades</title>
<author>
<name sortKey="Mak, Tze Minn" sort="Mak, Tze Minn" uniqKey="Mak T" first="Tze-Minn" last="Mak">Tze-Minn Mak</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author>
<name sortKey="Hanson, Brendon J" sort="Hanson, Brendon J" uniqKey="Hanson B" first="Brendon J." last="Hanson">Brendon J. Hanson</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Defence Medical and Environmental Research Institute, DSO National Laboratories</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author>
<name sortKey="Tan, Yee Joo" sort="Tan, Yee Joo" uniqKey="Tan Y" first="Yee-Joo" last="Tan">Yee-Joo Tan</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Infrastructure, Technology and Translational Division, Institute of Molecular and Cell Biology, A*STAR</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Department of Microbiology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">14-0168547</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0168547 INIST</idno>
<idno type="RBID">Pascal:14-0168547</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000079</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D40</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades</title>
<author>
<name sortKey="Mak, Tze Minn" sort="Mak, Tze Minn" uniqKey="Mak T" first="Tze-Minn" last="Mak">Tze-Minn Mak</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author>
<name sortKey="Hanson, Brendon J" sort="Hanson, Brendon J" uniqKey="Hanson B" first="Brendon J." last="Hanson">Brendon J. Hanson</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Defence Medical and Environmental Research Institute, DSO National Laboratories</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author>
<name sortKey="Tan, Yee Joo" sort="Tan, Yee Joo" uniqKey="Tan Y" first="Yee-Joo" last="Tan">Yee-Joo Tan</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Infrastructure, Technology and Translational Division, Institute of Molecular and Cell Biology, A*STAR</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Department of Microbiology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint>
<date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Characterization</term>
<term>Hemagglutinin</term>
<term>Influenza</term>
<term>Influenzavirus A(H5N1)</term>
<term>Monoclonal antibody</term>
<term>Multiple</term>
<term>Neutralization</term>
<term>Neutralizing antibody</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Caractérisation</term>
<term>Anticorps monoclonal</term>
<term>Multiple</term>
<term>Grippe</term>
<term>Anticorps neutralisant</term>
<term>Neutralisation</term>
<term>Hémagglutinine</term>
<term>Influenzavirus A(H5N1)</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The persistent evolution and circulation of highly pathogenic avian influenza H5N1 viruses pose a serious threat to global heath and hamper pandemic preparedness through conventional vaccine strategies. Combination passive immunotherapy using non-competing neutralizing antibodies has been proposed as a viable alternative to provide broad protection against drift variants. This necessitates the pre-pandemic production and characterization of potently neutralizing monoclonal antibodies (MAbs). One such antibody, MAb 9F4 was shown to provide heterologous protection against multiple H5N1 clade viruses, including one of the recently designated subclades, namely 2.3.4, through binding to a novel epitope, warranting its further development and characterization as a therapeutic candidate. In this study, the conversion of MAb 9F4 from mouse IgG
<sub>2b</sub>
to mouse-human chimeric (xi) IgG
<sub>1</sub>
and IgA
<sub>1</sub>
was achieved. These chimeric MAb versions were found to retain high degrees of binding and neutralizing activity against H5N1. The demonstration that xi-IgA
<sub>1</sub>
-9F4 retains a fairly high level of neutralizing activity, which is ˜10-fold lower than the corresponding xi-IgG
<sub>1</sub>
isotype, suggests that this MAb could be further developed and engineered for intranasal administration.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0166-3542</s0>
</fA01>
<fA02 i1="01">
<s0>ARSRDR</s0>
</fA02>
<fA03 i2="1">
<s0>Antivir. res.</s0>
</fA03>
<fA05>
<s2>107</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG">
<s1>Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>MAK (Tze-Minn)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>HANSON (Brendon J.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>TAN (Yee-Joo)</s1>
</fA11>
<fA14 i1="01">
<s1>NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Defence Medical and Environmental Research Institute, DSO National Laboratories</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Infrastructure, Technology and Translational Division, Institute of Molecular and Cell Biology, A*STAR</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>Department of Microbiology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20>
<s1>76-83</s1>
</fA20>
<fA21>
<s1>2014</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>18839</s2>
<s5>354000502765430110</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>14-0168547</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Antiviral research</s0>
</fA64>
<fA66 i1="01">
<s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>The persistent evolution and circulation of highly pathogenic avian influenza H5N1 viruses pose a serious threat to global heath and hamper pandemic preparedness through conventional vaccine strategies. Combination passive immunotherapy using non-competing neutralizing antibodies has been proposed as a viable alternative to provide broad protection against drift variants. This necessitates the pre-pandemic production and characterization of potently neutralizing monoclonal antibodies (MAbs). One such antibody, MAb 9F4 was shown to provide heterologous protection against multiple H5N1 clade viruses, including one of the recently designated subclades, namely 2.3.4, through binding to a novel epitope, warranting its further development and characterization as a therapeutic candidate. In this study, the conversion of MAb 9F4 from mouse IgG
<sub>2b</sub>
to mouse-human chimeric (xi) IgG
<sub>1</sub>
and IgA
<sub>1</sub>
was achieved. These chimeric MAb versions were found to retain high degrees of binding and neutralizing activity against H5N1. The demonstration that xi-IgA
<sub>1</sub>
-9F4 retains a fairly high level of neutralizing activity, which is ˜10-fold lower than the corresponding xi-IgG
<sub>1</sub>
isotype, suggests that this MAb could be further developed and engineered for intranasal administration.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B02S05</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Caractérisation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Characterization</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Caracterización</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Anticorps monoclonal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Monoclonal antibody</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Anticuerpo monoclonal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Multiple</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Multiple</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Múltiple</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Grippe</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Influenza</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Gripe</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Anticorps neutralisant</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Neutralizing antibody</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>anticuerpo neutralizante</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Neutralisation</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Neutralization</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Neutralización</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Hémagglutinine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Hemagglutinin</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Hemoaglutinina</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Influenzavirus A(H5N1)</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Influenzavirus A(H5N1)</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Infección</s0>
</fC07>
<fN21>
<s1>209</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D40 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001D40 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0168547
   |texte=   Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021